BIB
ProShares Ultra NASDAQ BiotechnologystockNASDAQETF
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 117.41 | 2026-11-12 | -7.44% | -15.669 |
| 1M | 107.09 | 2026-10-19 | +1.48% | 2.374 |
| 3M | 126.22 | 2026-08-19 | -13.90% | 2.357 |
| 6M | 77.30 | 2026-05-19 | +40.58% | 1.671 |
| 1Y | 76.39 | 2025-11-19 | +42.25% | 1.822 |
| 2Y | 53.52 | 2024-11-19 | +103.05% | — |
| 5Y | 85.22 | 2021-11-19 | +27.52% | 1.621 |
ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) stock price today is $108.67, and today's volume is 3,766. BIB is down 1.074% today. The 30 day average volume is 8,244. BIB market cap is $95.63M with 880,000 shares outstanding.
